NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
Viatris Inc. VTRS
8 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$14.3B
▼ 3.0% vs FY2024
EPS · FY25
$-3.00
Dividend / sh · FY25
$0.48
Payout · FY25
—
ROE · FY25
—
Net margin · FY25
-24.7%
Dividend coverage
-6.2×
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 14.3B
Revenue, FY2025 · full 8-year series below
Revenue
Net income
The company lost 25 cents on every revenue dollar this year.
Per share
USD -3.00
Diluted EPS, FY2025
EPS
Dividend
The dividend was paid in a year without profit.
Profitability
—
Return on equity, FY2025
ROE
Operating margin-18.7%
Net margin-24.7%
Return on assets-8.9%
Returned to shareholders
USD 497.9M
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacksUSD 497.9M
Share of profit-14.2%
Consecutive raises—
USD 497.9M in buybacks went back to shareholders in a year without profit.
Growth
+3.6% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−4.2%
+3.6%
Dividend / share
+0.0%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 37.2B
total assets, end of FY2025
Total assetsUSD 37.2B
CashUSD 1.3B
Gross debtUSD 14.4B
Net debtUSD 13.1B
Current ratio1.38×
History
8 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
Revenue $B
14.3
14.7
15.4
16.2
17.9
11.9
11.5
11.4
Operating income $B
−2.7
0.0
0.8
1.6
−0.0
−0.2
0.7
0.9
EBITDA $B
0.1
2.9
3.5
4.6
4.5
2.0
2.7
3.0
Income tax $B
−0.2
0.0
0.1
0.7
0.6
−0.1
0.1
−0.1
Net income $B
−3.5
−0.6
0.1
2.1
−1.3
−0.7
0.0
0.4
EPS, diluted $
−3.00
−0.53
0.05
1.71
−1.05
−1.11
0.03
0.68
Dividend / sh $
0.48
0.48
0.48
0.48
0.33
·
·
·
Payout %
·
·
·
·
·
·
·
·
ROE %
·
·
·
·
·
·
·
·
Shares out B
·
·
·
·
·
·
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
28 of 28
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed